Revolution Medicines
700 Saginaw Drive
Redwood City
California
94063
United States
124 articles about Revolution Medicines
-
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets
9/30/2021
Revolution Medicines, Inc. today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference being held on October 7-10, 2021.
-
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development SummitCompany’s Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs
9/15/2021
Revolution Medicines, Inc. today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021.
-
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Revolution Medicines, Inc. (Nasdaq: RVMD), today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Revolution Medicines Reports Second Quarter 2021 Financial Results and Update on Corporate Progress
8/11/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, announced its financial results for the second quarter and six months ended June 30, 2021, and provided a corporate update.
-
It's been a week of promising news for cancer research, with two possible treatment modalities reporting positive results.
-
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
6/24/2021
Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company’s First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor
-
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
6/10/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors.
-
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
6/2/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference.
-
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
5/18/2021
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2 nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.
-
Revolution Medicines Reports First Quarter 2021 Financial Results and Update on Corporate Progress
5/10/2021
Continued Advancement and Enrollment of Multiple RMC-4630 RAS Companion Inhibitor Combination Studies; Initiated Clinical Evaluation of RMC-5552
-
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
5/3/2021
Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees
-
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
4/21/2021
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced dosing of the first patient in a multicenter Phase 1/1b clinical trial evaluating RMC-5552, the company’s investigational first-in-class bi-steric mTORC1 inhibitor as a monotherapy
-
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
3/11/2021
Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors
-
Revolution Medicines to Participate in Upcoming Investor Conferences - Mar 09, 2021
3/9/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.
-
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
3/2/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced its financial results for the fourth quarter and year ended December 31, 2020, and provided a corporate update.
-
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
2/18/2021
Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2/8/2021
Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the closing of an underwritten public offering of 6,666,666 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions.
-
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock - Feb 04, 2021
2/4/2021
Revolution Medicines, Inc. announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions.
-
Revolution Medicines Announces Proposed Public Offering of Common Stock - Feb 01, 2021
2/1/2021
Revolution Medicines, Inc. announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock.
-
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference.